Kessler Exits Perrigo With Doors Open On Turnaround, Closed On Ireland, US Tax Disputes
At helm nearly five years with Perrigo continuing to navigate comprehensive turnaround with a target of returning to its historical profile of driving volume sales while keeping costs lower than is brand-name OTC drug competitors, he’s leaving at end of July.
You may also be interested in...
Year After Acquisition, Perrigo Waits For US Decision On HRA’s OTC Oral Contraceptive Switch
Wait will be as long as another three months to learn whether HRA will have approval to market OTC a product Perrigo estimates will have $100m in annual sales.
Reaching 'Transformation' In Turnaround Phase 1, Perrigo Looks To Build On Its Accomplishments
Day after releasing Q4 and full-year results, Perrigo announced launch of next chapter in its “3/5/7” makeover strategy. It reached annual growth of 3% for top line revenues in phase 1, aims for 5% operating income and 7% earnings per share growth in phase 2.
Perrigo Paying $309M To Settle $1.9Bn Irish Tax Assessment From Elan Merger
OTC private label/store brand giant announces Irish authorities allow it to pay $308.7m to settle a $1.9bn assessment for back taxes ordered in 2018 linked to Rx ingredient royalty rights it gained in its 2103 merger with Elan.